Research & Development

Leaders in R&D pull ahead by addressing established priorities and planning ahead for access

GSK leads with the largest pipeline comprised of projects that target well-established treatment priorities and has a structured process to develop access plans for all projects. Novartis and Johnson & Johnson follow, scoring well in all areas. 

1 GlaxoSmithKline plc
0 1 2 3 4 5
3.67

GlaxoSmithKline plc

Read more
2 Johnson & Johnson
0 1 2 3 4 5
3.33

Johnson & Johnson

Read more
3 Novartis AG
0 1 2 3 4 5
3.26

Novartis AG

Read more
4 Sanofi
0 1 2 3 4 5
2.83

Sanofi

Read more
5 Merck KGaA (Merck)
0 1 2 3 4 5
2.79

Merck KGaA (Merck)

Read more
6 AstraZeneca plc
0 1 2 3 4 5
2.78

AstraZeneca plc

Read more
7 Pfizer Inc.
0 1 2 3 4 5
2.73

Pfizer Inc.

Read more
8 Takeda Pharmaceutical Co. Ltd.
0 1 2 3 4 5
2.71

Takeda Pharmaceutical Co. Ltd.

Read more
9 Roche Holding AG
0 1 2 3 4 5
2.54

Roche Holding AG

Read more
10 Eisai Co. Ltd.
0 1 2 3 4 5
2.11

Eisai Co. Ltd.

Read more
11 Boehringer Ingelheim GmbH
0 1 2 3 4 5
1.77

Boehringer Ingelheim GmbH

Read more
12 AbbVie Inc.
0 1 2 3 4 5
1.75

AbbVie Inc.

Read more
13 Gilead Sciences Inc.
0 1 2 3 4 5
1.71

Gilead Sciences Inc.

Read more
14 Astellas Pharma Inc.
0 1 2 3 4 5
1.32

Astellas Pharma Inc.

Read more
15 Merck & Co., Inc. (MSD)
0 1 2 3 4 5
1.28

Merck & Co., Inc. (MSD)

Read more
16 Bristol Myers Squibb Co.
0 1 2 3 4 5
1.19

Bristol Myers Squibb Co.

Read more
17 Bayer AG
0 1 2 3 4 5
1.01

Bayer AG

Read more
18 Novo Nordisk A/S
0 1 2 3 4 5
0.98

Novo Nordisk A/S

Read more
19 Eli Lilly & Co.
0 1 2 3 4 5
0.88

Eli Lilly & Co.

Read more
20 Daiichi Sankyo Co. Ltd.
0 1 2 3 4 5
0.84

Daiichi Sankyo Co. Ltd.

Read more
0 1 2 3 4 5

The ranking above shows the position and score of each company in the 2021 Index. Click on a company's name to go to its full report card.

Get in touch

Back to top |